NVTR Nuvectra Corporation

(d)     Exhibits

Forward-Looking Statements

This Current Report on Form 8-K contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based only on the Company’s current beliefs, expectations and assumptions regarding the future of the Company’s business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions, and therefore they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and may be outside of the Company’s control. The Company’s performance may differ materially from those indicated in the forward-looking statements, and you should not rely on any of these forward-looking statements. Any forward-looking statement made by the Company is based only on information currently available to the Company and speaks only as of the date on which it is made. Important factors that could cause the Company’s actual results to differ materially from those indicated in the forward-looking statements include: (i) the Company’s ability to successfully scale and continue operations during the court-supervised process; (ii) the Company’s ability to successfully sell assets or take other steps to maximize value and address its financial obligations under the court-supervised process; (iii) potential adverse effects of the court-supervised process on the Company’s liquidity and results of operations; (iv) the potential of adverse rulings in the court-supervised process, including the possibility that the Company may fail to obtain timely approval with respect to the motions it has filed or will file in the future; (v) the risk that motions filed by third parties could protract, or impede the Company’s objectives under, the court-supervised process; (vi) employee attrition and the Company’s ability to retain management and other key personnel due to distractions and uncertainties, including the Company’s ability to provide adequate compensation and benefits during the court-supervised process; (vii) the Company’s ability to maintain relationships with suppliers, customers, employees and other third parties and regulatory authorities as a result of the court-supervised process; (viii) the effects of the reorganization petitions on the Company and on the interests of its various constituents, including holders of the Company’s common stock; (ix) the detrimental effect the reorganization petitions could have on the Company’s ability to access the capital markets in the future, if desired; (x) the length of time that the Company will operate under the court-supervised process and the continued availability of operating capital during the pendency of the proceedings; (xi) increased administrative and legal costs related to the court-supervised process and other litigation and inherent risks involved in a reorganization process; (xii) the Company’s ability to successfully market its Algovita Spinal Cord Stimulation System (“Algovita”) and to develop enhancements or improvements to Algovita; (xiii) the uncertainty and timing of obtaining regulatory approvals in the United States and Europe for the Company’s Virtis sacral neuromodulation system; (xiv) the scope of protection for the Company’s intellectual property rights covering Algovita and other products using the Company’s neurostimulation technology platform, along with any product enhancements or improvements; and (xv) the Company’s compliance with all regulatory and legal requirements regarding implantable medical devices and interactions with healthcare professionals. Please see the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K and in the Company’s other quarterly and periodic filings for a description of these and other risks and uncertainties. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.